期刊
NEUROLOGICAL SCIENCES
卷 31, 期 -, 页码 S289-S293出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-010-0345-y
关键词
Natalizumab; Multiple sclerosis; Antibodies; monoclonals/adverse effects; Antibodies; monoclonals/therapeutic use; Product surveillance
资金
- Swedish national board of health and welfare
- BiogenIdec Sweden AB
- MerckSerono
- sanofi aventis
- Bayer-Schering
A post-marketing surveillance program was implemented to monitor the safety and open label efficacy of natalizumab since its launch in Sweden August 2006. Patients are registered in the Swedish multiple sclerosis (MS)-registry that has a nationwide coverage using a standardized follow-up that includes EDSS, MSSS, SDMT, MSIS-29, and recording of adverse events (AEs). As of 31 January, 2010, 1,115 patients had been included, of which 363 were treated >= 24 months. Dropout rate was 10%, mainly due to planned pregnancy. Serious AEs were rare, but included three cases of progressive multifocal leukoencephalopathy (PML), none of which had received previous immunosuppressive therapy. All analyzed clinical outcome parameters showed significant improvements compared to baseline for patients exceeding 24 months of treatment. Our results demonstrate good general tolerability and sustained efficacy of natalizumab for patients with severe MS, though the risk of PML remains a concern.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据